Various Factors Influencing the Enantiomers of Warfarin Pharmacokinetics: A Systematic Review of Population Pharmacokinetics
- 1,3,
- 1*,
- 2,
- 3
- 1Department of Pharmaceutics, JSS College of Pharmacy, Ootacamund, Tamil Nadu, India.
- 2Department of Pharmacy Practice, JSS College of Pharmacy, Ootacamund, Tamil Nadu, India.
- 3Scitus Pharma Services Pvt. Ltd., Kattupakkam, Chennai, Tamil Nadu, India.
Published in Journal of Pharmacology and Pharmacotherapeutics
Correspondence: G.N.K. Ganesh
Department of Pharmaceutics, JSS College of Pharmacy, Ootacamund, Tamil Nadu, India.
Email: gnk@jssuni.edu.in
Copyright: © 2023 The Author(s). This is an open access article.
Published: Jan 1, 2023, Received: Jul 25, 2023, Accepted: Sep 29, 2023
Abstract
Warfarin is the most commonly prescribed anti-coagulant medication. Warfarin’s pharmacokinetics (PK) in its enantiomeric form have been reported to be highly variable. Five population pharmacokinetic model studies for warfarin were identified in this systematic review. This review summarized these studies and reported on various factors affecting warfarin PK. Most studies reported a one-compartment model with first-order absorption and elimination for both S-warfarin and R-warfarin. Warfarin disposition has been reported to be influenced by various factors, including gender, age, genetic variation, body surface area (BSA), concurrent drug, weight, and ethnicity. So, all of these factors must be considered when addressing this pharmacokinetic variability. These models should undergo an external evaluation to confirm their generalizability and to support model-informed dosing in clinical settings.
Subject
Readers Also Viewed
Clinical Outcomes and Management of Post-varicocelectomy on Male Fertility: A Comprehensive Review
Mohammad Akbar Hossain
Jan 1, 2026
Exploring Interleukin-6 Inhibitor Antibodies in Combatting SARS-CoV-2 and its Mutated Variants: Challenges and Future Directions
Mohammed Ali Bakkari, Gassem Ghoal, Fahad Y. Sabei
Jan 1, 2025
Pharmacogenomics Meets Generative AI: Transforming Clinical Trial Design with Large Language Models
Annisa Fatharani, Ali Alsayegh
Jan 1, 2026